RU2013142258A - Замещенные аминомасляные производные в качестве ингибиторов неприлизина - Google Patents
Замещенные аминомасляные производные в качестве ингибиторов неприлизина Download PDFInfo
- Publication number
- RU2013142258A RU2013142258A RU2013142258/04A RU2013142258A RU2013142258A RU 2013142258 A RU2013142258 A RU 2013142258A RU 2013142258/04 A RU2013142258/04 A RU 2013142258/04A RU 2013142258 A RU2013142258 A RU 2013142258A RU 2013142258 A RU2013142258 A RU 2013142258A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- alkylene
- compound according
- halogen
- benzyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract 73
- 150000001875 compounds Chemical class 0.000 claims abstract 39
- 229910052736 halogen Inorganic materials 0.000 claims abstract 27
- 150000002367 halogens Chemical class 0.000 claims abstract 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 23
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 17
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000005843 halogen group Chemical group 0.000 claims abstract 4
- 125000002541 furyl group Chemical group 0.000 claims abstract 3
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001721 carbon Chemical group 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- -1 2 -imidazolyl Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- 125000006239 protecting group Chemical group 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 5
- 239000002464 receptor antagonist Substances 0.000 claims 5
- 229940044551 receptor antagonist Drugs 0.000 claims 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical group C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 4
- 239000012964 benzotriazole Chemical group 0.000 claims 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 4
- 235000010290 biphenyl Nutrition 0.000 claims 4
- 239000004305 biphenyl Substances 0.000 claims 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 4
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 150000003852 triazoles Chemical group 0.000 claims 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- PRQUBDQDCAULSW-UHFFFAOYSA-N 2-(2h-triazol-4-yl)pyridine Chemical compound N1N=NC(C=2N=CC=CC=2)=C1 PRQUBDQDCAULSW-UHFFFAOYSA-N 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000006267 biphenyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 101100482220 Sulfurisphaera tokodaii (strain DSM 16993 / JCM 10545 / NBRC 100140 / 7) triC gene Proteins 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 239000000674 adrenergic antagonist Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000005103 alkyl silyl group Chemical group 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 1
- 102100022749 Aminopeptidase N Human genes 0.000 claims 1
- 102400000345 Angiotensin-2 Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 claims 1
- 108010049990 CD13 Antigens Proteins 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- CQLNESDVGMHFMU-UHFFFAOYSA-N N1=CNC2=C1C=CC=C2.C2=CC=C1C=CC3=CC=CC4=CC=C2C1=C34 Chemical group N1=CNC2=C1C=CC=C2.C2=CC=C1C=CC3=CC=CC4=CC=C2C1=C34 CQLNESDVGMHFMU-UHFFFAOYSA-N 0.000 claims 1
- 108020001621 Natriuretic Peptide Proteins 0.000 claims 1
- 102000004571 Natriuretic peptide Human genes 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 229940127473 Prostaglandin Receptor Agonists Drugs 0.000 claims 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000001384 anti-glaucoma Effects 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003793 antidiarrheal agent Substances 0.000 claims 1
- 229940125714 antidiarrheal agent Drugs 0.000 claims 1
- 239000003965 antinociceptive agent Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003601 chymase inhibitor Substances 0.000 claims 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229960005156 digoxin Drugs 0.000 claims 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002857 endothelin converting enzyme inhibitor Substances 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000407 monoamine reuptake Effects 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000000692 natriuretic peptide Substances 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 150000003536 tetrazoles Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical group C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
- 229930192474 thiophene Chemical group 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 239000002536 vasopressin receptor antagonist Substances 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 0 CC(*)(C*(CC(C(C)(*)C=C1)=CC=C1C1=CC=CC=C*1*)NP)C(*)=O Chemical compound CC(*)(C*(CC(C(C)(*)C=C1)=CC=C1C1=CC=CC=C*1*)NP)C(*)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Соединение формулы I:,где:Rвыбран из -ORи -NRR;Rвыбран из -CHOH, -CHOP(O)(OH)и -CHOC(O)CH(R)NH; или Rвместе с Rобразует -CHO-CRR- или вместе с Rобразует -CHO-C(O)-;Rвыбран из H и -CH, или вместе с Rобразует -CH-O-CH-;Z выбран из -CH- и -N-;X обозначает -Cгетероарил;Rотсутствует или выбран из H; галогена; -Cалкилен-OH; -NH; -Cалкила; -CF; -Cциклоалкила; -Cалкилен-O-Cалкила; -C(O)R; -Cалкилен-COOR; -C(O)NRR; -NHC(O)R; =O; -NO; -C(CH)=N(OH); фенила, в случае необходимости замещенного одной или двумя группами, независимо выбранными из галогена, -OH, -CF, -OCH, -NHC(O)CHи фенила; нафталенила; пиридинила; пиразинила; пиразолила, в случае необходимости замещенного метилом; тиофенила, в случае необходимости замещенного метилом или галогеном; фуранила; и -CH-морфолинила; и R, в случае его присутствия, присоединен к атому углерода;Rотсутствует или выбран из H; -OH; -Cалкила; -Cалкилен-COOR; -CHOC(O)CH(R)NH; -OCHOC(O)CH(R)NH; -OCHOC(O)CH; -CHOP(O)(OH); -CHCH(OH)CHOH; -CH[CH(CH)]-NHC(O)O-Cалкила; пиридинила; и фенила или бензила, в случае необходимости замещенного одной или более группами, выбранными из галогена, -COOR5, -OCH, -OCFи -SCF; и R, в случае его присутствия, присоединен к атому углерода или азота;или Rи Rвместе образуют -фенилен-O-(CH)- или -фенилен-O-CH-CHOH-CH-;а=0 или 1; Rвыбран из галогена, -CH, -CFи -CN;b=0 или целое число от 1 до 3; каждый Rнезависимо выбран из галогена, -ОН, -CH, -OCHи -CF;Rвыбран из H, -Cалкила, -Cалкилен-Cарила, -Cалкилен-Cгетероарила, -Cциклоалкила, -[(CH)O]CH, -Cалкилен-OC(O)R, -Cалкилен-NRR, -Cалкилен-C(O)R, -Cалкиленморфолинила, -Cалкилен-SO-Cалкила;Rвыбран из -Cалкила, -O-Cалкила, -Cциклоалкила, -O-Cциклоалкила, фенила, -O-фенила, -NRR, -CH[CH(CH)]-NH, -CH[CH(CH)]-NHC(O)O-Cалкила и -CH(NH)CHCOOCH; и Rи Rнезависимо выбраны из H, -Cалкила и бензила, или Rи Rвместе образуют -(CH)-, -C(O)-(CH)- или -(CH)O(CH)-; Rвыбран из -O-Cалкила, -O-бензила и -NRR; и Rобозначает -Cал�
Claims (33)
1. Соединение формулы I:
где:
R1 выбран из -OR7 и -NR8R9;
R2a выбран из -CH2OH, -CH2OP(O)(OH)2 и -CH2OC(O)CH(R37)NH2; или R2a вместе с R7 образует -CH2O-CR18R19- или вместе с R8 образует -CH2O-C(O)-;
R2b выбран из H и -CH3, или вместе с R2a образует -CH2-O-CH2-;
Z выбран из -CH- и -N-;
X обозначает -C1-9гетероарил;
R3 отсутствует или выбран из H; галогена; -C0-5алкилен-OH; -NH2; -C1-6алкила; -CF3; -C3-7циклоалкила; -C0-2алкилен-O-C1-6алкила; -C(O)R20; -C0-1алкилен-COOR21; -C(O)NR22R23; -NHC(O)R24; =O; -NO2; -C(CH3)=N(OH); фенила, в случае необходимости замещенного одной или двумя группами, независимо выбранными из галогена, -OH, -CF3, -OCH3, -NHC(O)CH3 и фенила; нафталенила; пиридинила; пиразинила; пиразолила, в случае необходимости замещенного метилом; тиофенила, в случае необходимости замещенного метилом или галогеном; фуранила; и -CH2-морфолинила; и R3, в случае его присутствия, присоединен к атому углерода;
R4 отсутствует или выбран из H; -OH; -C1-6алкила; -C1-2алкилен-COOR35; -CH2OC(O)CH(R36)NH2; -OCH2OC(O)CH(R36)NH2; -OCH2OC(O)CH3; -CH2OP(O)(OH)2; -CH2CH(OH)CH2OH; -CH[CH(CH3)2]-NHC(O)O-C1-6алкила; пиридинила; и фенила или бензила, в случае необходимости замещенного одной или более группами, выбранными из галогена, -COOR35, -OCH3, -OCF3 и -SCF3; и R4, в случае его присутствия, присоединен к атому углерода или азота;
или R3 и R4 вместе образуют -фенилен-O-(CH2)1-3- или -фенилен-O-CH2-CHOH-CH2-;
а=0 или 1; R5 выбран из галогена, -CH3, -CF3 и -CN;
b=0 или целое число от 1 до 3; каждый R6 независимо выбран из галогена, -ОН, -CH3, -OCH3 и -CF3;
R7 выбран из H, -C1-8алкила, -C1-3алкилен-C6-10арила, -C1-3алкилен-C1-9гетероарила, -C3-7циклоалкила, -[(CH2)2O]1-3CH3, -C1-6алкилен-OC(O)R10, -C1-6алкилен-NR12R13, -C1-6алкилен-C(O)R31, -C0-6алкиленморфолинила, -C1-6алкилен-SO2-C1-6алкила;
R10 выбран из -C1-6алкила, -O-C1-6алкила, -C3-7циклоалкила, -O-C3-7циклоалкила, фенила, -O-фенила, -NR12R13, -CH[CH(CH3)2]-NH2, -CH[CH(CH3)2]-NHC(O)O-C1-6алкила и -CH(NH2)CH2COOCH3; и R12 и R13 независимо выбраны из H, -C1-6алкила и бензила, или R12 и R13 вместе образуют -(CH2)3-6-, -C(O)-(CH2)3- или -(CH2)2O(CH2)2-; R31 выбран из -O-C1-6алкила, -O-бензила и -NR12R13; и R32 обозначает -C1-6алкил или -C0-6алкилен-C6-10арил;
R8 выбран из H, -OH, -OC(O)R14, -CH2COOH, -O-бензила, -пиридила и -OC(S)NR15R16; R14 выбран из H, -C1-6алкила, -C6-10арила, -OCH2-C6-10арила, -CH2O-C6-10арила и -NR15R16; и R15 и R16 независимо выбраны из H и -C1-4алкила;
R9 выбран из H, -C1-6алкила и -C(O)-R17; и R17 выбран из H, -C1-6алкила, -C3-7циклоалкила, -C6-10арила и -C1-9гетероарила;
R18 и R19 независимо выбраны из H, -C1-6алкила и -O-C3-7циклоалкила, или R18 и R19 вместе образуют =O;
R20 выбран из H и -C1-6алкила;
R21 и R35 независимо выбраны из H, -C1-6алкила, -C1-3алкилен-C6-10арила, -C1-3алкилен-C1-9гетероарила, -C3-7циклоалкила, -[(CH2)2O]1-3CH3, -C1-6алкилен-OC(O)R25, -C1-6алкилен-NR27R28, -C1-6алкилен-C(O)R33, -C0-6алкиленморфолинила, -C1-6алкилен-SO2-C1-6алкила,
R25 выбран из -C1-6алкила, -O-C1-6алкила, -C3-7циклоалкила, -O-C3-7циклоалкила, фенила, -O-фенила, -NR27R28, -CH[CH(CH3)2]-NH2, -CH[CH(CH3)2]-NHC(O)O-C1-6алкила и -CH(NH2)CH2COOCH3; R27 и R28 независимо выбраны из H, -C1-6алкила и бензила; или R27 и R28 вместе образуют -(CH2)3-6-, -C(O)-(CH2)3- или -(CH2)2O(CH2)2-; R33 выбран из -O-C1-6алкила, -О-бензила и -NR27R28; и R34 обозначает -C1-6алкил или -C0-6алкилен-C6-10арил;
R22 и R23 независимо выбраны из H, -C1-6алкила, -CH2COOH, -(CH2)2OH; -(CH2)2OCH3, -(CH2)2SO2NH2, -(CH2)2N(CH3)2, -C0-1алкилен-C3-7циклоалкила и -(CH2)2-имидазолила; или R22 и R23 вместе образуют насыщенный или частично ненасыщенный -C3-5гетероцикл, в случае необходимости замещенный галогеном, -ОН, -COOH или -CONH2; и в случае необходимости содержащий атом кислорода в кольце;
R24 выбран из -C1-6алкила; -C0-1алкилен-O-C1-6алкила; фенила, в случае необходимости замещенного галогеном или -OCH3; и -C1-9гетероарила;
R36 выбран из H, -CH(CH3)2, фенила и бензила; и
R37 выбран из H, -CH(CH3)2, фенила и бензила;
где каждая алкильная группа в R1, R3 и R4 может быть замещена 1-8 атомами фтора; и;
где метиленовый линкер на бифениле может быть замещен одной или двумя -C1-6алкильными группами или циклопропилом;
или его фармацевтически приемлемая соль.
2. Соединение по п.1, где X выбран из пиразола, имидазола, триазола, бензотриазола, фурана, пиррола, тетразола, пиразина, тиофена, оксазола, изоксазола, тиазола, изотиазола, оксадиазола, тиадиазола, пиридазина, пиридина, пиримидина, пирана, бензимидазола, бензоксазола, бензотиазола, пиридилимидазола и пиридилтриазола.
3. Соединение по п.2, где X выбран из пиразола, имидазола, триазола, бензотриазола, оксазола, изоксазола, пиримидина, пиридазина, бензимидазола, пирана и пиридилтриазола.
5. Соединение по п.1, где R1 выбран из -OR7 и -NR8R9; R7 обозначает H; R8 обозначает H или -OH; и R9 обозначает H.
6. Соединение по п.1, где:
R1 обозначает -OR7; и R7 выбран из -C1-8алкила, -C1-3алкилен-C6-10арила, -C1-3алкилен-C1-9гетероарила, -C3-7циклоалкила, -[(CH2)2O]1-3CH3, -C1-6алкилен-OC(O)R10, -C1-6алкилен-NR12R13, -C1-6алкилен-C(O)R31, -C0-6алкиленморфолинила, -C1-6алкилен-SO2-C1-6алкила,
R1 обозначает -NR8R9; R8 выбран из -OC(O)R14, -CH2COOH, -О-бензила, пиридила и -OC(S)NR15R16; и R9 обозначает H; или
R1 обозначает -NR8R9; R8 выбран из -OC(O)R14, -CH2COOH, -О-бензила, пиридила и -OC(S)NR15R16; и R9 обозначает -C1-6алкил или -C(O)R17;
R1 обозначает -NR8R9; R8 выбран из H или -OH; и R9 обозначает -C1-6алкил или -C(O)R17;
R1 обозначает -OR7, и R2a вместе с R7 образует -CH2O-CR18R19-; или
R1 обозначает -NR8R9, и R2a вместе с R8 образует -CH2O-C(O)-.
7. Соединение по п.1, где R1 обозначает -OR7; R7 выбран из H, -C1-8алкила, -C1-3алкилен-C6-10арила, -[(CH2)2O]1-3CH3, -C1-6алкилен-OC(O)R10, -C1-6алкилен-NR12R13, -C1-6алкилен-C(O)R31, -C0-6алкиленморфолинила, -C1-6алкилен-SO2-C1-6алкила,
R10 выбран из -C1-6алкила, -O-C1-6алкила, -O-C3-7циклоалкила, -CH[CH(CH3)2]-NH2 и -CH[CH(CH3)2]-NHC(O)O-C1-6алкила; R12 и R13 обозначают -C1-6алкил или вместе образуют -(CH2)3-6-, -C(O)-(CH2)3- или -(CH2)2O(CH2)2-; R31 выбран из -O-C1-6алкила, -О-бензила и -NR12R13; и R32 обозначает -CH3.
8. Соединение по п.1, где R2a обозначает -CH2OH и R2b обозначает H.
9. Соединение по п.1, где R2a выбран из -CH2OH, -CH2OP(O)(ОН)2 и -CH2OC(O)CH(R37)NH2; R2b обозначает -CH3; и R37 обозначает -CH(CH3)2.
10. Соединение по п.1, где R2a вместе с R7 образует -CH2O-CR18R19-; R18 и R19 независимо выбраны из H и -C1-6алкила; и R2b обозначает -CH3.
11. Соединение по п.1, где Z обозначает -CH-.
12. Соединение по п.1, где Z обозначает -N-.
13. Соединение по п.1, где R3 отсутствует или выбран из H; галогена; -C0-5алкилен-OH; -NH2; -C1-6алкила; -CF3; -C3-7циклоалкила; -C0-2алкилен-O-C1-6алкила; -C(O)R20; -C0-1алкилен-COOR21; -C(O)NR22R23; -NHC(O)R24; =O; -NO2; -C(CH3)=N(ОН); фенила, в случае необходимости замещенного одной или двумя группами, независимо выбранными из галогена, -OH, -CF3, -OCH3, -NHC(O)CH3 и фенила; нафталинила; пиридинила; пиразинила; пиразолила, в случае необходимости замещенного метилом; тиофенила, в случае необходимости замещенного метилом или галогеном; фуранила; и -CH2-морфолинила; и R21 обозначает H.
14. Соединение по п.1, где R3 обозначает -C0-1алкилен-COOR21; и R21 выбран из -C1-6алкила, -C1-3алкилен-C6-10арила, -C1-3алкилен-C1-9гетероарила, -C3-7циклоалкила, -[(CH2)2O]1-3CH3, -C1-6алкилен-OC(O)R25, -C1-6алкилен-NR27R28, -C1-6алкилен-C(O)R33, -C0-6алкиленморфолинила, -C1-6алкилен-SO2-C1-6алкила,
15. Соединение по п.1, где R3 выбран из H; галогена; -C0-5алкилен-OH; -C1-6алкила; -C(O)R20; -C0-1алкилен-COOR21; -C(O)NR22R23; =O; фенила, замещенного одним галогеном; и пиридинила; R20 обозначает -C1-6алкил; R21 обозначает H; и R22 и R23 независимо выбраны из -C1-6алкила, -(CH2)2OCH3 и -C3-7циклоалкила; или R22 и R23 вместе образуют насыщенный -C3-5гетероцикл.
16. Соединение по п.1, где R4 отсутствует или выбран из H; -OH; -C1-6алкила; -C1-2алкилен-COOR35; -CH2OC(O)CH(R36)NH2; -CH2CH(О)CH2OH; пиридинила; и фенила или бензила, в случае необходимости замещенного одной или более группами, выбранными из галогена, -COOR35, -OCH3, -OCF3 и -SCF3; и R35 обозначает H.
17. Соединение по п.1, где R4 выбран из -OCH2OC(O)CH3; -CH2OP(O)(ОН)2; -C1-2алкилен-COOR35; и фенила или бензила, замещенного по меньшей мере одной группой -COOR35; где R35 выбран из -C1-6алкила, -C1-3алкилен-C6-10арила, -C1-3алкилен-C1-9гетероарила, -C3-7циклоалкила, -[(CH2)2O]1-3CH3, -C1-6алкилен-OC(O)R25, -C1-6алкилен-NR27R28, -C1-6алкилен-C(O)R33, -C0-6алкиленморфолинила, -C1-6алкилен-SO2-C1-6алкила,
18. Соединение по п.1, где R4 выбран из H, -OH, -C1-6алкила, -CH2OC(O)CH(R36)NH2, -CH[CH(CH3)2]-NHC(O)O-C1-6алкила и бензила.
19. Соединение по п.1, где а=0.
20. Соединение по п.1, где b=0, или b=1 и R6 обозначает галоген.
21. Соединение по п.1, где метиленовый линкер на дифениле замещен двумя группами -CH3.
22. Соединение по п.1, где R1 обозначает -OR7; R7 выбран из H, -C1-8алкила, -C1-3алкилен-C6-10арила, -[(CH2)2O]1-3CH3, -C1-6алкилен-OC(O)R10, -C1-6алкилен-NR12R13, -C1-6алкилен-C(O)R31, -C0-6алкиленморфолинила, -C1-6алкилен-SO2-C1-6алкила,
R10 выбран из -C1-6алкила, -O-C1-6алкила, -O-C3-7циклоалкила, -CH[CH(CH3)2]-NH2 и -CH[CH(CH3)2]-NHC(O)O-C1-6алкила; R12 и R13 обозначают -C1-6алкил или вместе образуют -(CH2)3-6-, -C(O)-(CH2)3- или -(CH2)2O(CH2)2-; R31 выбран из -O-C1-6алкила, -О-бензила и -NR12R13; и R32 обозначает -CH3; R2a обозначает -CH2OH, и R2b обозначает H; или R2a выбран из -CH2OH, -CH2OP(O)(ОН)2 и -CH2OC(O)CH(R37)NH2, R2b обозначает -CH3, и R37 обозначает -CH(CH3)2; или R2a вместе с R7 образует -CH2O-CR18R19-, R18 и R19 независимо выбраны из H и -C1-6алкила, и R2b обозначает -CH3; Z обозначает -CH-; X выбран из пиразола, имидазола, триазола, бензотриазола, оксазола, изоксазола, пиримидина, пиридазина, бензимидазола, пирана и пиридилтриазола; R3 выбран из H; галогена; -C0-5алкилен-OH; -C1-6алкила; -C(O)R20; -C0-1алкилен-COOR21; -C(O)NR22R23; =O; фенила, замещенного одним галогеном; и пиридинила; R20 обозначает -C1-6алкил; R21 обозначает H; R22 и R23 независимо выбраны из -C1-6алкила, -(CH2)2OCH3 и -C3-7циклоалкила; или R22 и R23 вместе образуют насыщенный -C3-5гетероцикл; R4 выбран из H, -OH, -C1-6алкила, -CH2OC(O)CH(R36)NH2, -CH2OP(O)(ОН)2, -CH[CH(CH3)2]-NHC(O)O-C1-6алкила и бензила; а=0; b=0, или b=1, и R6 обозначает галоген; и метиленовый линкер на дифениле в случае необходимости замещен двумя группами -CH3.
23. Соединение по п.1, где X выбран из пиразола, триазола, бензотриазола, оксазола, изоксазола и пиримидина; R3 выбран из H; галогена; -C0-5алкилен-OH; -C1-6алкила; -C0-1алкилен-COOR21; -C(O)NR22R23; =O; фенила, замещенного одним галогеном; и пиридинила; R21 обозначает H; R22 и R23 вместе образуют насыщенный -C3-5гетероцикл; R4 выбран из H и -OH; а=0; b=0, или b=1, и R6 обозначает галоген; и метиленовый линкер на дифениле в случае необходимости замещен двумя группами -CH3.
24. Способ получения соединения по любому из пп.1-23, включающий стадию сочетания соединения формулы 1 с соединением формулы 2:
с получением соединения формулы I; где P1 обозначает H или защитную группу для аминогруппы, выбранную из трет-бутоксикарбонила, тритила, бензилоксикарбонила, 9-флуоренилметоксикарбонила, формила, триметилсилила и трет-бутилдиметилсилила; и причем способ дополнительно включает удаление защитной группы от соединения формулы 1, когда P1 обозначает защитную группу для аминогруппы.
25. Промежуточное соединение, пригодное для использования в синтезе соединения по любому из пп.1-23, имеющее формулу 1:
где P1 обозначает H или защитную группу для аминогруппы, выбранную из трет-бутоксикарбонила, тритила, бензилоксикарбонила, 9-флуоренилметоксикарбонила, формила, триметилсилила и трет-бутилдиметилсилила; или его соль.
26. Способ получения соединения по любому из пп.1-23, включающий стадию удаления защитной группы от соединения, выбранного из:
или его соли; где R1P выбран из -O-P3, -NHP2 и -NH(O-P4); R3P выбран из -C0-5алкилен-O-P4, -C0-1алкилен-COO-P3 и фенила, замещенного -O-P4; R4P выбран из -O-P4; -C1-2алкилен-COO-P3; и фенила или бензила, замещенного -СОО-P3; P2 обозначает защитную группу для аминогруппы, выбранную из трет-бутоксикарбонила, тритила, бензилоксикарбонила, 9-флуоренилметоксикарбонила, формила, триметилсилила и трет-бутилдиметилсилила; P3 обозначает защитную группу для карбоксигруппы, выбранную из метила, этила, трет-бутила, бензила, п-метоксибензила, 9-флуоренилметила, триметилсилила, трет-бутилдиметилсилила и дифенилметила; и P4 обозначает защитную группу для гидроксила, выбранную из -C1-6алкила, триС1-6алкилсилила, -C1-6алканоила, бензоила, бензила, п-метоксибензила, 9-флуоренилметила и дифенилметила.
27. Промежуточное соединение, пригодное для использования в синтезе соединения по любому из пп.1-23, выбранное из:
или его соль; где где R1P выбран из -O-P3, -NHP2 и -NH(O-P4); R3P выбран из -C0-5алкилен-O-P4, -C0-1алкилен-COO-P3 и фенила, замещенного -O-P4; R4P выбран из -O-P4; -C1-2алкилен-COO-P3; и фенила или бензила, замещенного -СОО-P3; P2 обозначает защитную группу для аминогруппы, выбранную из трет-бутоксикарбонила, тритила, бензилоксикарбонила, 9-флуоренилметоксикарбонила, формила, триметилсилила и трет-бутилдиметилсилила; P3 обозначает защитную группу для карбоксигруппы, выбранную из метила, этила, трет-бутила, бензила, п-метоксибензила, 9-флуоренилметила, триметилсилила, трет-бутилдиметилсилила и дифенилметила; и P4 обозначает защитную группу для гидроксила, выбранную из -C1-6алкила, триС1-6алкилсилила, -C1-6алканоила, бензоила, бензила, п-метоксибензила, 9-флуоренилметила и дифенилметила.
28. Фармацевтическая композиция, включающая соединение по любому из пп.1-23 и фармацевтически приемлемый носитель.
29. Фармацевтическая композиция по п.28, дополнительно содержащая терапевтическое средство, выбранное из антагонистов рецептора аденозина, антагонистов α-адренергического рецептора, антагонистов β1-адренергического рецептора, агонистов β2-адренергического рецептора, антагонистов β-адренергического рецептора/антагонистов α1-рецептора двойного действия, брейкеров конечного продукта усиленного гликозилирования, антагонистов альдостерона, ингибиторов альдостерон синтазы, ингибиторов аминопептидазы N, андрогенов, ингибиторов ангиотензин-превращающего фермента и ингибиторов ангиотензин-превращающего фермента/неприлизина двойного действия, активаторов и стимуляторов ангиотензин-превращающего фермента 2, вакцин ангиотензина-II, антикоагулянтов, антидиабетических средств, антидиарейных средств, средств против глаукомы, антилипидных средств, антиноцицептивных средств, антитромбических средств, антагонистов рецептора AT1 и антагонистов рецептора AT1/ингибиторов неприлизина двойного действия и многофункциональных блокаторов рецептора ангиотензина, антагонистов рецептора брадикинина, блокаторов кальциевых каналов, ингибиторов химазы, дигоксина, диуретиков, агонистов допамина, ингибиторов эндотелин-превращающего фермента, антагонистов рецептора эндотелина, ингибиторов HMG-CoA редуктазы, эстрогенов, агонистов и/или антагонистов рецептора эстрогена, ингибиторов обратного захвата моноамина, миорелаксантов, натрийуретических пептидов и их аналогов, антагонистов рецептора выведения натрийуретического пептида, ингибиторов неприлизина, доноров оксида азота, нестероидных противовоспалительных средств, антагонистов рецептора N-метил-d-аспартата, агонистов рецептора опиоидов, ингибиторов фосфодиэстеразы, аналогов простагландина, агонистов рецептора простагландина, ингибиторов ренина, селективных ингибиторов обратного захвата серотонина, блокатора натриевого канала, растворимых стимуляторов и активаторов гуанилатциклазы, трициклических антидепрессантов, антагонистов рецептора вазопрессина и их комбинаций.
30. Фармацевтическая композиция по п.29, в которой терапевтическое средство представляет собой антагонист рецептора AT1.
31. Соединение по любому из пп.1-23 для применения в терапии.
32. Соединение по п.31 для применения в лечении гипертензии, сердечной недостаточности или заболевания почек.
33. Применение соединения по любому из пп.1-23 для получения лекарственного средства для лечения гипертензии, сердечной недостаточности или заболевания почек.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161443827P | 2011-02-17 | 2011-02-17 | |
US61/443,827 | 2011-02-17 | ||
PCT/US2012/025365 WO2012112742A1 (en) | 2011-02-17 | 2012-02-16 | Substituted aminobutyric derivatives as neprilysin inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013142258A true RU2013142258A (ru) | 2015-04-10 |
RU2604522C2 RU2604522C2 (ru) | 2016-12-10 |
Family
ID=45814661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013142258/04A RU2604522C2 (ru) | 2011-02-17 | 2012-02-16 | Замещенные аминомасляные производные в качестве ингибиторов неприлизина |
Country Status (19)
Country | Link |
---|---|
US (5) | US8481044B2 (ru) |
EP (1) | EP2675795B1 (ru) |
JP (2) | JP5959065B2 (ru) |
KR (1) | KR101854874B1 (ru) |
CN (1) | CN103380119B (ru) |
AR (1) | AR085280A1 (ru) |
AU (1) | AU2012217615B2 (ru) |
BR (1) | BR112013020996A8 (ru) |
CA (1) | CA2825737C (ru) |
CO (1) | CO6781518A2 (ru) |
ES (1) | ES2582640T3 (ru) |
IL (1) | IL227594A (ru) |
MX (1) | MX342212B (ru) |
MY (1) | MY163394A (ru) |
RU (1) | RU2604522C2 (ru) |
SG (1) | SG192815A1 (ru) |
TW (1) | TWI548622B (ru) |
WO (1) | WO2012112742A1 (ru) |
ZA (1) | ZA201305826B (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120041702A (ko) | 2009-05-28 | 2012-05-02 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체 |
NZ610983A (en) | 2010-12-15 | 2014-10-31 | Theravance Biopharma R & D Ip Llc | Neprilysin inhibitors |
CA2819153A1 (en) | 2010-12-15 | 2012-06-21 | Theravance, Inc. | Neprilysin inhibitors |
CA2825737C (en) | 2011-02-17 | 2018-11-13 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
ES2564275T3 (es) | 2011-02-17 | 2016-03-21 | Theravance Biopharma R&D Ip, Llc | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
CA2835220A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
US8513244B2 (en) | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
AR089955A1 (es) | 2012-02-15 | 2014-10-01 | Theravance Inc | Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico |
AR089954A1 (es) * | 2012-02-15 | 2014-10-01 | Theravance Inc | Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico |
EP2855464B1 (en) | 2012-05-31 | 2016-10-26 | Theravance Biopharma R&D IP, LLC | Nitric oxide donor neprilysin inhibitors |
MX356260B (es) | 2012-06-08 | 2018-05-21 | Theravance Biopharma R&D Ip Llc | Inhibidores de la neprilisina. |
WO2013184898A1 (en) | 2012-06-08 | 2013-12-12 | Theravance, Inc. | Neprilysin inhibitors |
CA2879697C (en) * | 2012-08-08 | 2020-07-07 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
EA026989B1 (ru) | 2013-02-14 | 2017-06-30 | Новартис Аг | Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью |
PL2956464T3 (pl) | 2013-02-14 | 2018-08-31 | Novartis Ag | Podstawione pochodne bisfenylowe kwasu butanowofosfonowego jako inhibitory nep (neutralnej endopeptydazy) |
ME02937B (me) | 2013-03-05 | 2018-04-20 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
MX2016009759A (es) * | 2014-01-30 | 2016-11-17 | Theravance Biopharma R&D Ip Llc | Inhibidores de neprilisina. |
MX2016009760A (es) * | 2014-01-30 | 2016-11-08 | Theravance Biopharma R&D Ip Llc | Inhibidores de neprilisina. |
ES2923002T3 (es) | 2015-02-11 | 2022-09-22 | Theravance Biopharma R&D Ip Llc | Acido (2S,4R)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxailamino)-2-hidroximetil-2-metilpentanoico como inhibidor de la neprilisina |
WO2016133803A1 (en) | 2015-02-19 | 2016-08-25 | Theravance Biopharma R&D Ip, Llc | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
KR20220035991A (ko) * | 2016-03-08 | 2022-03-22 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | (2s,4r)-5-(5'-클로로-2'-플루오로-[1,1'-비페닐]-4-일)-2-(에톡시메틸)-4-(3-히드록시이속사졸-5-카르복사미도)-2-메틸펜탄산 결정 및 그 용도 |
JP7263369B2 (ja) | 2018-01-03 | 2023-04-24 | エコラボ ユーエスエー インコーポレイティド | 腐食防止剤としてのベンゾトリアゾール誘導体 |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
WO2020110008A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
JP2022509184A (ja) | 2018-11-27 | 2022-01-20 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化(上海)新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
CN109912486B (zh) * | 2019-04-25 | 2022-09-27 | 东北制药集团股份有限公司 | 一种联苯甲基内酰胺化合物的制备方法 |
TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4189604A (en) | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
US4206232A (en) | 1976-05-10 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Relieving hypertension with carboxyalkylacylamino acids |
IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
US4906615A (en) | 1980-12-18 | 1990-03-06 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
US4939261A (en) | 1984-06-08 | 1990-07-03 | Ciba-Geigy Corporation | N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase |
EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
KR880007441A (ko) | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
FR2623498B1 (fr) | 1987-11-24 | 1990-04-06 | Bioprojet Soc Civ | Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques |
GB8820844D0 (en) | 1988-09-05 | 1988-10-05 | Pfizer Ltd | Therapeutic agents |
US5599951A (en) | 1989-09-15 | 1997-02-04 | Societe Civile Bioprojet | Amino acid derivatives, the process for their preparation and their applications to therapy |
US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
JP3576193B2 (ja) * | 1993-12-03 | 2004-10-13 | 第一製薬株式会社 | ビフェニルメチル置換バレリルアミド誘導体 |
DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
AU5687396A (en) | 1995-04-21 | 1996-11-07 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
GB0119305D0 (en) | 2001-04-12 | 2001-10-03 | Aventis Pharma Gmbh | Mercaptoacetylamide derivatives,a process for their preparation and their use |
CA2505299C (en) * | 2002-11-19 | 2012-11-13 | Galderma Research & Development, S.N.C. | Novel biaromatic compunds which activate ppary type receptors, and use therof in cosmetic or pharmaceutical compositions |
WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
JP5715339B2 (ja) | 2007-01-12 | 2015-05-07 | ノバルティス アーゲー | 5−ビフェニル−4−アミノ−2−メチルペンタン酸の製造方法 |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
AR070176A1 (es) | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
CN103896796B (zh) | 2009-05-28 | 2016-04-27 | 诺华股份有限公司 | 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物 |
KR20120041702A (ko) | 2009-05-28 | 2012-05-02 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
JP5600183B2 (ja) | 2010-01-22 | 2014-10-01 | ノバルティス アーゲー | 中性エンドペプチダーゼ阻害剤の中間体およびその調製方法 |
WO2012028257A1 (de) * | 2010-08-31 | 2012-03-08 | Rheinmetall Waffe Munition Gmbh | Vorrichtung und verfahren zur erzeugung einer wirksamen nebelwand bzw. nebelwolke |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
CA2819153A1 (en) * | 2010-12-15 | 2012-06-21 | Theravance, Inc. | Neprilysin inhibitors |
NZ610983A (en) * | 2010-12-15 | 2014-10-31 | Theravance Biopharma R & D Ip Llc | Neprilysin inhibitors |
ES2564275T3 (es) | 2011-02-17 | 2016-03-21 | Theravance Biopharma R&D Ip, Llc | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
CA2825737C (en) | 2011-02-17 | 2018-11-13 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
US8513244B2 (en) | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
US8686184B2 (en) | 2011-05-31 | 2014-04-01 | Theravance, Inc. | Neprilysin inhibitors |
CA2835220A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
AR089955A1 (es) | 2012-02-15 | 2014-10-01 | Theravance Inc | Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico |
AR089954A1 (es) | 2012-02-15 | 2014-10-01 | Theravance Inc | Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico |
EP2855464B1 (en) | 2012-05-31 | 2016-10-26 | Theravance Biopharma R&D IP, LLC | Nitric oxide donor neprilysin inhibitors |
MX356260B (es) | 2012-06-08 | 2018-05-21 | Theravance Biopharma R&D Ip Llc | Inhibidores de la neprilisina. |
WO2013184898A1 (en) | 2012-06-08 | 2013-12-12 | Theravance, Inc. | Neprilysin inhibitors |
CA2879697C (en) | 2012-08-08 | 2020-07-07 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
ME02937B (me) | 2013-03-05 | 2018-04-20 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
-
2012
- 2012-02-16 CA CA2825737A patent/CA2825737C/en not_active Expired - Fee Related
- 2012-02-16 US US13/398,015 patent/US8481044B2/en active Active
- 2012-02-16 CN CN201280009330.6A patent/CN103380119B/zh active Active
- 2012-02-16 MX MX2013009499A patent/MX342212B/es active IP Right Grant
- 2012-02-16 KR KR1020137023969A patent/KR101854874B1/ko active IP Right Grant
- 2012-02-16 ES ES12708194.1T patent/ES2582640T3/es active Active
- 2012-02-16 MY MYPI2013002706A patent/MY163394A/en unknown
- 2012-02-16 RU RU2013142258/04A patent/RU2604522C2/ru not_active IP Right Cessation
- 2012-02-16 SG SG2013062401A patent/SG192815A1/en unknown
- 2012-02-16 WO PCT/US2012/025365 patent/WO2012112742A1/en active Application Filing
- 2012-02-16 BR BR112013020996A patent/BR112013020996A8/pt not_active IP Right Cessation
- 2012-02-16 AU AU2012217615A patent/AU2012217615B2/en not_active Ceased
- 2012-02-16 EP EP12708194.1A patent/EP2675795B1/en active Active
- 2012-02-16 JP JP2013554587A patent/JP5959065B2/ja not_active Expired - Fee Related
- 2012-02-17 AR ARP120100547A patent/AR085280A1/es unknown
- 2012-02-17 TW TW101105349A patent/TWI548622B/zh not_active IP Right Cessation
-
2013
- 2013-06-03 US US13/908,619 patent/US8853427B2/en active Active
- 2013-07-22 IL IL227594A patent/IL227594A/en active IP Right Grant
- 2013-08-01 ZA ZA2013/05826A patent/ZA201305826B/en unknown
- 2013-08-14 CO CO13193461A patent/CO6781518A2/es not_active Application Discontinuation
-
2014
- 2014-08-27 US US14/470,072 patent/US9334245B2/en not_active Expired - Fee Related
-
2015
- 2015-12-18 JP JP2015246942A patent/JP2016094452A/ja not_active Withdrawn
-
2016
- 2016-04-06 US US15/091,854 patent/US9724359B2/en active Active
-
2017
- 2017-06-30 US US15/638,821 patent/US10130642B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013142258A (ru) | Замещенные аминомасляные производные в качестве ингибиторов неприлизина | |
RU2013132524A (ru) | Ингибиторы неприлизина | |
RU2013132533A (ru) | Ингибиторы неприлизина | |
JP2014508755A5 (ru) | ||
JP2014505734A5 (ru) | ||
JP2015523980A5 (ru) | ||
JP2015505298A5 (ru) | ||
RU2014122109A (ru) | Ингибиторы неприлизина | |
AU2019210414B2 (en) | Pyridone derivative, composition thereof and application thereof as anti-influenza drug | |
RU2015107751A (ru) | Ингибиторы неприлизина | |
RU2014153578A (ru) | Ингибиторы неприлизина | |
JP2014503534A5 (ru) | ||
JP2015525215A5 (ru) | ||
HRP20110445T1 (hr) | Spojevi bisadenozina kao agonisti receptora adenozina a2a | |
MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
JP2007530450A5 (ru) | ||
JP2015523988A5 (ru) | ||
WO2011054834A1 (en) | Benzimidazole-imidazole derivatives | |
PL185999B1 (pl) | Nowe zastosowanie inhibitorów cGMP-fosfodiesterazy | |
JP2006528621A5 (ru) | ||
UY31507A1 (es) | Derivados de piridina activadores de guanilato ciclasa soluble | |
RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
EA200400762A1 (ru) | Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции | |
AR056218A1 (es) | Composicion farmaceutica de liberacion mantenida comprimido de liberacion inmediata y comprimido oralmente administrable que comprende una sla soluble en agua d 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2- hidroxi-1-(hidroximetil)etil] amino}pirido (2,3-d)pirimidin-7(8h)-ona; dicho compues | |
JP2019059775A (ja) | C型肝炎ウイルスの大環状二環式阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190217 |